



THORACIC



For illustrative
purposes only

cytalux[®] 
(pafolacianine) injection

See cancer in real time.

REIMBURSEMENT GUIDE

Using the CYTALUX® Reimbursement Guide:

The CYTALUX Reimbursement Guide is intended to provide current and available reimbursement information to hospitals and health care providers so that they may better understand the billing and coding requirements for CYTALUX (pafolaclanine) injection.

DISCLAIMER

Information described in the CYTALUX Reimbursement Guide is intended solely for use as a resource tool to assist hospital inpatient billing staff regarding reimbursement issues. Any determination regarding if and how to seek reimbursement should be made only by the appropriate members of the hospital inpatient staff, and in consideration of the procedure performed or therapy provided to a specific patient. There may be some payers that require specific information for billing imaging agents on inpatient claims. Therefore, please consult the applicable payer organization with regard to local or actual coverage, reimbursement policies, and determination processes and always confirm adherence to specific payer rules and guidelines.

On Target Laboratories does not recommend or endorse the use of any particular diagnosis or procedure code(s) and make no determination if or how reimbursement may be available. Of important note, reimbursement codes and payment, as well as health policy and legislation, are subject to continual change; information contained in this version of the CYTALUX Reimbursement Guide is current as of September 2023.



CYTALUX Reimbursement Support

1 (765) 269-4419

reimbursement@ontargetlabs.com

The CYTALUX Reimbursement Support Line assists hospitals, healthcare providers and patients and is composed of a comprehensive reimbursement support program that is available to provide support for CYTALUX reimbursement and access issues.

The CYTALUX Reimbursement Support Program does not file claims or appeal claims for callers, nor can it guarantee that you will be successful in obtaining reimbursement. Third-party payment for medical products and services is affected by numerous factors, not all of which can be anticipated or resolved by the Reimbursement Support Line.

Table of Contents

▶ **CYTALUX® Overview**

▶ **Coding for Lung Surgery**

National Drug Code (NDC)

Healthcare Common Procedure Coding System (HCPCS Code)

New Technology Add-on Payment (NTAP)

Procedure Coding System (ICD-10-PCS)

Thoracic Surgical ICD-10 Procedure Codes

Clinical Modification Diagnosis Codes (ICD-10-CM)

Medicare Severity Diagnosis Related Group (MS-DRG) Coverage

Professional Current Procedural Terminology (CPT) Codes

Revenue Code

▶ **Coverage**


CYTALUX Public and Private Payer Information

Sample Claim Form

▶ **Important Safety Information**

CYTALUX® Overview

CYTALUX® MOLECULE



What is CYTALUX?

CYTALUX is the only IV-delivered molecular imaging agent that illuminates lung cancer intraoperatively for real-time localization of pulmonary lesions.

CYTALUX Indications

CYTALUX is an FDA approved optical imaging agent indicated as an adjunct for intraoperative identification of:

- Malignant lesions in adult patients with ovarian cancer.
- Malignant and non-malignant pulmonary lesions in adult patients with known or suspected cancer in the lung.

Please consult the full **Prescribing Information** for additional preparation and storage instructions.

Coding for Lung Cancer

NATIONAL DRUG CODE (NDC)

The NDC, or National Drug Code, is a unique 10-digit (drug packaging) or 11-digit (claim filing), 3-segment number, and a universal product identifier for drugs in the United States. The 3 segments of the NDC identify: the labeler, the product, and the commercial package size.

There may be times when a payer may require our NDC number to be on the inpatient claim therefore it is important that you confirm the NDC billing instructions with each payer, as their requirements may vary. Proper billing of an NDC requires the 11-digit number in a 5-4-2 format.

CYTALUX NDC NUMBER

10 DIGIT NUMBER 81052-138-10

11 DIGIT NUMBER 81052-0138-10

HCPCS Code

Healthcare Common Procedure Coding System (HCPCS) is a standardized code system necessary for medical providers to submit healthcare claims to Medicare and other health insurances in a consistent and orderly manner.

HCPCS Level II Code

A9603	Injection, pafolacianine, 0.1 mg
-------	----------------------------------

New Technology Add-On Payment (NTAP)

NTAP a term used in the U.S. healthcare system to refer to a payment mechanism that provides additional reimbursement to hospitals for the use of certain new and innovative medical technologies that are deemed to be of significant clinical benefit. NTAP, which is part of the CMS Inpatient Prospective Payment System (IPPS), was set up to support the adoption of cutting-edge technologies that have demonstrated substantial clinical improvement and ensure early availability to Medicare patients. This incremental payment seeks to mitigate financial disincentives for use on Medicare and Tricare patients by providing hospitals with an add-on payment to help offset the technology's cost.

CYTALUX was 1 of only 8 new technologies to be granted the NTAP, effective Oct 1, 2023.

Details of NTAP

Eligible Facilities	- Acute care hospitals participating in the inpatient prospective payment system. - Military hospitals and clinics under the TRICARE program
Qualified Patients	Traditional Medicare and dual-eligible (Medicare-Medicaid) fee-for-service patients or TRICARE patients whose case totals exceed the MS-DRG rate payment
Add-on Payment	- The NTAP is limited to the lesser of 65% of the cost of the new technology or 65% of the amount by which the cost of the case exceeds the MS-DRG payment. - The maximum add-on payment for CYTALUX is \$2,762.50 for fiscal year (FY) 2024 (reassessed annually)
Effective Date	October 1, 2023
Duration	NTAP is approved for up to 3 years; the maximum add-on payment amount is reassessed annually

HOW TO CODE FOR ADD-ON PAYMENT

Hospitals must report the ICD-10-PCS code on claim forms for procedures related to CYTALUX to receive the add-on payment for eligible inpatient cases.

ICD-10- PCS Procedure Coding System

Effective 10/01/2023, the Centers for Medicare & Medicaid Services (CMS) created 5 new PCS codes that captures the PCS method value Fluorescence Guided Procedure and the PCS qualifier value Pafolacianine and applies them to the fourth character body region values and applicable approaches. These changes enable the capture of additional detail for fluorescence-guided procedures that use Pafolacianine.

ICD-10 CODE: 8E0

- ▶ **Section** 8 Other Procedures
- ▶ **Body System** E Physiological Systems and Anatomical Regions
- ▶ **Operation** 0 Other Procedures: Methodologies which attempt to remediate or cure a disorder or disease

▶ Body Region	▶ Approach	▶ Method	▶ Qualifier
W Trunk Region	0 Open 3 Percutaneous 4 Percutaneous Endoscopic 7 Via Natural or Artificial Opening 8 Via Natural or Artificial Opening Endoscopic	E Fluorescence Guided Procedure	N Pafolacianine Z No Qualifier

ICD-10-PCS Codes

Our new ICD-10-PCS code can be used for discharges effective October 1, 2023.

8E0W0EN	Fluorescence guided procedure of trunk region using pafolacianine, open approach
8E0W3EN	Fluorescence guided procedure of trunk region using pafolacianine, percutaneous approach
8E0W4EN	Fluorescence guided procedure of trunk region using pafolacianine, percutaneous endoscopic approach
8E0W7EN	Fluorescence guided procedure of trunk region using pafolacianine, via natural or artificial opening
8E0W8EN	Fluorescence guided procedure of trunk region using pafolacianine, via natural or artificial opening endoscopic

For additional information, please consult the current ICD-10-PCS manual. Some individual payers may require specific accommodations for billing imaging agents on inpatient claims. Always conform to specific payer rules and guidelines.

Thoracic Surgical ICD-10 Procedure Codes

0BTC0ZZ	Resection of Right Upper Lung Lobe, Open Approach
0BTC4ZZ	Resection of Right Upper Lung Lobe, Percutaneous Endoscopic Approach
0BTD0ZZ	Resection of Right Middle Lung Lobe, Open Approach
0BTD4ZZ	Resection of Right Middle Lung Lobe, Percutaneous Endoscopic Approach
0BTF0ZZ	Resection of Right Lower Lung Lobe, Open Approach
0BTF4ZZ	Resection of Right Lower Lung Lobe, Percutaneous Endoscopic Approach
0BTG0ZZ	Resection of Left Upper Lung Lobe, Open Approach
0BTG4ZZ	Resection of Left Upper Lung Lobe, Percutaneous Endoscopic Approach
0BTH0ZZ	Resection of Lung Lingula, Open Approach
0BTH4ZZ	Resection of Lung Lingula, Percutaneous Endoscopic Approach
0BTJ0ZZ	Resection of Left Lower Lung Lobe, Open Approach
0BTJ4ZZ	Resection of Left Lower Lung Lobe, Percutaneous Endoscopic Approach
0BTK0ZZ	Resection of Right Lung, Open Approach
0BTK4ZZ	Resection of Right Lung, Percutaneous Endoscopic Approach
0BTL0ZZ	Resection of Left Lung, Open Approach
0BTL4ZZ	Resection of Left Lung, Percutaneous Endoscopic Approach
0BBC0ZZ	Excision of Right Upper Lung Lobe, Open Approach
0BBC4ZZ	Excision of Right Upper Lung Lobe, Percutaneous Endoscopic Approach
0BBC8ZZ	Excision of Right Upper Lung Lobe, Via Natural or Artificial Opening Endoscopic
0BBD0ZZ	Excision of Right Middle Lung Lobe, Open Approach
0BBD4ZZ	Excision of Right Middle Lung Lobe, Percutaneous Endoscopic Approach
0BBD8ZZ	Excision of Right Middle Lung Lobe, Via Natural or Artificial Opening Endoscopic
0BBF0ZZ	Excision of Right Lower Lung Lobe, Open Approach

0BBF4ZZ	Excision of Right Lower Lung Lobe, Percutaneous Endoscopic Approach
0BBF8ZZ	Excision of Right Lower Lung Lobe, Via Natural or Artificial Opening Endoscopic
0BBG0ZZ	Excision of Left Upper Lung Lobe, Open Approach
0BBG4ZZ	Excision of Left Upper Lung Lobe, Percutaneous Endoscopic Approach
0BBG8ZZ	Excision of Left Upper Lung Lobe, Via Natural or Artificial Opening Endoscopic
0BBH0ZZ	Excision of Lung Lingula, Open Approach
0BBH4ZZ	Excision of Lung Lingula, Percutaneous Endoscopic Approach
0BBH8ZZ	Excision of Lung Lingula, Via Natural or Artificial Opening Endoscopic
0BBJ0ZZ	Excision of Left Lower Lung Lobe, Open Approach
0BBJ4ZZ	Excision of Left Lower Lung Lobe, Percutaneous Endoscopic Approach
0BBJ8ZZ	Excision of Left Lower Lung Lobe, Via Natural or Artificial Opening Endoscopic
0BBK0ZZ	Excision of Right Lung, Open Approach
0BBK4ZZ	Excision of Right Lung, Percutaneous Endoscopic Approach
0BBK8ZZ	Excision of Right Lung, Via Natural or Artificial Opening Endoscopic
0BBL0ZZ	Excision of Left Lung, Open Approach
0BBL4ZZ	Excision of Left Lung, Percutaneous Endoscopic Approach
0BBL8ZZ	Excision of Left Lung, Via Natural or Artificial Opening Endoscopic
0BBM0ZZ	Excision of Bilateral Lungs, Open Approach
0BBM4ZZ	Excision of Bilateral Lungs, Percutaneous Endoscopic Approach
0BBM8ZZ	Excision of Bilateral Lungs, Via Natural or Artificial Opening Endoscopic

ICD-10-CM Clinical Modification Diagnosis Codes

The ICD-10-CM is used to classify diagnoses and reasons for visits in all health care settings. Always check with the payers guidelines to verify ICD-10-CM requirements, for individual rules may vary. Below is a range of potential ICD-10-CM diagnosis codes that may be related to a diagnosis within CYTALUX approved label.

Potential ICD-10-CM Clinical Modification Diagnosis Codes

C3411	Malignant neoplasm of upper lobe, right bronchus, or lung
C3412	Malignant neoplasm of upper lobe, left bronchus or lung
C342	Malignant neoplasm of middle lobe, bronchus, or lung
C3430	Malignant neoplasm of lower lobe, unspecified bronchus or lung
C3431	Malignant neoplasm of lower lobe, right bronchus or lung
C3432	Malignant neoplasm of lower lobe, left bronchus or lung
C3481	Malignant neoplasm of overlapping sites of right bronchus and lung
C3490	Malignant neoplasm of unspecified part of unspecified bronchus or lung
C3491	Malignant neoplasm of unspecified part of right bronchus or lung
C3492	Malignant neoplasm of unspecified part of left bronchus or lung
C7800	Secondary malignant neoplasm of unspecified lung
C7801	Secondary malignant neoplasm of right lung
C7802	Secondary malignant neoplasm of left lung
C7A090	Malignant carcinoid tumor of the bronchus and lung
D0221	Carcinoma in situ of right bronchus and lung
D0222	Carcinoma in situ of left bronchus and lung
D381	Neoplasm of uncertain behavior of trachea, bronchus and lung
C3480	Malignant neoplasm of overlapping sites of unspecified bronchus and lung
C3482	Malignant neoplasm of overlapping sites of left bronchus and lung

Medicare Severity Diagnosis Related Group (MS-DRG)

MS-DRG means Medicare severity-diagnosis-related group. It's a system of classifying patient hospital stays. Within the system, Medicare classifies groups to facilitate service payments. CYTALUX is an inpatient drug and will be bundled by payers into hospital payment rates (MS-DRGs), all patient refined (APR DRGs), or other DRGs specific to the individual payer's internal methodology. The DRG assignment depends on the diagnosis and the procedure with which CYTALUX will be bundled. There are 3 MS-DRGs that represent the procedures involving CYTALUX and are shown in the table below. This table may not be inclusive of all MS-DRGs or other non-MS-DRGs that may be used for CYTALUX. Only 1 MS-DRG should be assigned to a patient for a particular hospital admission.

Potential MS-DRG Codes

163	MAJOR CHEST PROCEDURES WITH MCC
164	MAJOR CHEST PROCEDURES WITH CC
165	MAJOR CHEST PROCEDURES WITHOUT CC MCC

Revenue Codes

Revenue codes may also be used to report services and supplies that are utilized during treatment.

Suggested Revenue Codes

0360	Operating Room Services General
0250	Pharmacy General

Professional Current Procedural Terminology (CPT) Codes

In addition to facility inpatient reimbursement, some hospitals also bill out professional physician fees separate from the inpatient procedure. Below is a list meant to serve as a guide of commonly used professional fees; it is not exhaustive, and individual circumstances and payer rules will determine coding.

Potential CPT Codes for Thoracic Surgery

CPT Code	Description	Total RVUs ¹	Work RVUs ¹	2026 Medicare National Avg. ²
32096	Thoracotomy, with diagnostic biopsy(ies) of lung infiltrate(s) (eg, wedge, incisional), unilateral	22.88	13.41	\$764.21
32097	Thoracotomy, with diagnostic biopsy(ies) of lung nodule(s) or mass(es) (eg, wedge, incisional), unilateral	23.05	13.41	\$769.89
32480	Removal of lung, other than pneumonectomy; single lobe (lobectomy)	41.99	25.17	\$1,402.50
32482	Removal of lung, other than pneumonectomy; 2 lobes (bilobectomy)	45.03	26.75	\$1,504.04
32484	Removal of lung, other than pneumonectomy; single segment (segmentectomy)	40.51	24.75	\$1,353.07
32486	Removal of lung, other than pneumonectomy; with circumferential resection of segment of bronchus followed by broncho-bronchial anastomosis (sleeve lobectomy)	65.15	41.81	\$2,176.07
32503	Resection of apical lung tumor (eg, Pancoast tumor), including chest wall resection, rib(s) resection(s), neurovascular dissection, when performed; without chest wall reconstruction(s)	50.69	30.95	\$1,693.09
32505	Thoracotomy; with therapeutic wedge resection (eg, mass, nodule), initial	26.79	15.36	\$894.81
+32506	Thoracotomy; with therapeutic wedge resection (eg, mass, nodule), each additional resection, ipsilateral (List separately in addition to code for primary procedure)	4.23	2.93	\$141.29
+32507	Thoracotomy; with diagnostic wedge resection followed by anatomic lung resection (List separately in addition to code for primary procedure)	4.23	2.93	\$141.29
32663	Thoracoscopy, surgical; with lobectomy (single lobe)	39.48	24.02	\$1,318.67
32666	Thoracoscopy, surgical; with therapeutic wedge resection (eg, mass, nodule), initial unilateral	25.12	14.14	\$839.03
+32667	Thoracoscopy, surgical; with therapeutic wedge resection (eg, mass, nodule), each additional resection, ipsilateral surgical; (List separately in addition to code for primary procedure)	4.24	2.93	\$141.62
+32668	Thoracoscopy, surgical; with diagnostic wedge resection followed by anatomic lung resection (List separately in addition to code for primary procedure)	4.25	2.93	\$141.95
32669	Thoracoscopy, surgical; with removal of a single lung segment (segmentectomy)	37.95	22.94	\$1,267.56
32670	Thoracoscopy, surgical; with removal of two lobes (bilobectomy)	44.91	27.81	\$1,500.03

Potential CPT Codes for Infusion

CPT Code	Description
96365	Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour
+96366	Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); each additional hour (List separately in addition to code for primary procedure)

¹ CMS 2026 Physician Fee Schedule, released November 2025

² 2026 payment calculated using 2026 conversion factor of \$33.40

+ CPT® code with a + symbol is listed in addition to the primary code

Coverage

CYTALUX® PUBLIC AND PRIVATE PAYER COVERAGE INFORMATION COVERAGE

Medicare

Medicare is a federally funded health insurance program that was established as part of the Social Security Act of 1965, which provides coverage to 49 million beneficiaries, and is administered through the following 4 benefit categories:

Part A Hospital Insurance	Covers inpatient hospital, skilled nursing facility, hospice and certain home healthcare services. Reimbursement is a prospective payment with a single payment inclusive of all service, supplies, and drugs.
Part B Medical Insurance	Covers outpatient services, physician services and physician-administered drugs in the office and hospital outpatient settings.
Part C Medicare Advantage	Administered by managed care plans which are accountable for providing traditional Medicare services/benefits; however, they have flexibility to offer additional benefits
Part D Medicare Prescription Drug Coverage	Covers self-administered drugs through Part C or standalone Prescription Drug Plans administered by private organizations.

BECAUSE CYTALUX IS A HOSPITAL-ADMINISTERED PRODUCT, IT IS COVERED UNDER MEDICARE PART A.

Private Payers

Each private payer plan administers its own benefits and determines specific coverage and payment policies. Some private payers may follow Medicare's coverage policies, while other private payers may have more restrictive or less restrictive benefits. Private payers will consider covering CYTALUX when used for its FDA-approved indication. They may implement restrictions, such as requiring prior authorization and/or other utilization controls. Reimbursement may also vary significantly by the specific contracts that are negotiated between the hospitals and private payers.

Medicaid

Most states have direct administration of the program and also contract with managed care organizations to administer the program. Medicaid programs and their MCOs may follow Medicare's coverage policies, while others may create their own coverage guidelines. Typically, Medicaid will consider covering CYTALUX when used for its FDA-approved indication. Some programs may implement restrictions, such as requiring prior authorization and/or other utilization controls.

Sample Claim Form: CMS-1450/UB-04

Form CMS-1450, also known as the UB-04, is the standard claim form to bill Medicare Administrative Contractors (MACs).

1		2		3a PAT. CNTRL. # b. MED. REG. #		4. TYPE OF BILL	
8 PATIENT NAME		9 PATIENT ADDRESS		5 FED. TAX NO.		6 STATEMENT COVERS PERIOD FROM THROUGH	
10 BIRTHDATE		11 SEX		12 DATE		13 HR 14 TYPE 15 SRC 16 DHR 17 STAT	
18		19		20		21	
22		23		24		25	
26		27		28		29 ACCT STATE	
30		31		32		33	
34		35		36		37	
38		39		40		41	
42		43		44		45	
46		47		48		49	
50		51		52		53	
54		55		56		57	
58		59		60		61	
62		63		64		65	
66		67		68		69	
70		71		72		73	
74		75		76		77	
78		79		80		81	
82		83		84		85	
86		87		88		89	
90		91		92		93	
94		95		96		97	
98		99		100		101	
102		103		104		105	
106		107		108		109	
110		111		112		113	
114		115		116		117	
118		119		120		121	
122		123		124		125	
126		127		128		129	
130		131		132		133	
134		135		136		137	
138		139		140		141	
142		143		144		145	
146		147		148		149	
150		151		152		153	
154		155		156		157	
158		159		160		161	
162		163		164		165	
166		167		168		169	
170		171		172		173	
174		175		176		177	
178		179		180		181	
182		183		184		185	
186		187		188		189	
190		191		192		193	
194		195		196		197	
198		199		200		201	
202		203		204		205	
206		207		208		209	
210		211		212		213	
214		215		216		217	
218		219		220		221	
222		223		224		225	
226		227		228		229	
230		231		232		233	
234		235		236		237	
238		239		240		241	
242		243		244		245	
246		247		248		249	
250		251		252		253	
254		255		256		257	
258		259		260		261	
262		263		264		265	
266		267		268		269	
270		271		272		273	
274		275		276		277	
278		279		280		281	
282		283		284		285	
286		287		288		289	
290		291		292		293	
294		295		296		297	
298		299		300		301	
302		303		304		305	
306		307		308		309	
310		311		312		313	
314		315		316		317	
318		319		320		321	
322		323		324		325	
326		327		328		329	
330		331		332		333	
334		335		336		337	
338		339		340		341	
342		343		344		345	
346		347		348		349	
350		351		352		353	
354		355		356		357	
358		359		360		361	
362		363		364		365	
366		367		368		369	
370		371		372		373	
374		375		376		377	
378		379		380		381	
382		383		384		385	
386		387		388		389	
390		391		392		393	
394		395		396		397	
398		399		400		401	
402		403		404		405	
406		407		408		409	
410		411		412		413	
414		415		416		417	
418		419		420		421	
422		423		424		425	
426		427		428		429	
430		431		432		433	
434		435		436		437	
438		439		440		441	
442		443		444		445	
446		447		448		449	
450		451		452		453	
454		455		456		457	
458		459		460		461	
462		463		464		465	
466		467		468		469	
470		471		472		473	
474		475		476		477	
478		479		480		481	
482		483		484		485	
486		487		488		489	
490		491		492		493	
494		495		496		497	
498		499		500		501	
502		503		504		505	
506		507		508		509	
510		511		512		513	
514		515		516		517	
518		519		520		521	
522		523		524		525	
526		527		528		529	
530		531		532		533	
534		535		536		537	
538		539		540		541	
542		543		544		545	
546		547		548		549	
550		551		552		553	
554		555		556		557	
558		559		560		561	
562		563		564		565	
566		567		568		569	
570		571		572		573	
574		575		576		577	
578		579		580		581	
582		583		584		585	
586		587		588		589	
590		591		592		593	
594		595		596		597	
598		599		600		601	
602		603		604		605	
606		607		608		609	
610		611		612		613	
614		615		616		617	
618		619		620		621	
622		623		624		625	
626		627		628		629	
630		631		632		633	
634		635		636		637	
638		639		640		641	
642		643		644		645	
646		647		648		649	
650		651		652		653	
654		655		656		657	
658		659		660		661	
662		663		664		665	
666		667		668		669	
670		671		672		673	
674		675		676		677	
678		679		680		681	
682		683		684		685	
686		687		688		689	
690		691		692		693	
694		695		696		697	
698		699		700		701	
702		703		704		705	
706		707		708		709	
710		711		712		713	
714		715		716		717	
718		719		720		721	
722		723		724		725	
726		727		728		729	
730		731		732		733	
734		735		736		737	
738		739		740		741	
742		743		744		745	
746		747		748		749	
750		751		752		753	
754		755		756		757	
758		759		760		761	
762		763		764		765	
766		767		768		769	
770		771		772		773	
774		775		776		777	
778		779		780		781	
782		783		784		785	
786		787		788		789	
790		791		792		793	
794		795		796		797	
798		799		800		801	
802		803		804		805	
806		807		808		809	
810		811		812		813	
814		815		816		817	
818		819		820		821	
822		823		824		825	
826		827		828		829	
830		831		832		833	
834		835		836		837	
838		839		840		841	
842		843		844		845	
846		847		848		849	
850		851		852		853	
854		855		856		857	
858		859		860		861	
862		863		864		865	
866		867		868		869	
870		871		872		873	
874		875		876		877	
878		879		880		881	
882		883		884		885	
886		887		888		889	
890		891		892		893	
894		895		896		897	
898		899		900		901	
902		903		904		905	
906		907		908		909	
910		911		912		913	
914		915		916		917	
918		919		920		921	
922		923		924		925	
926		927		928		929	
930		931		932		933	
934		935		936		937	
938		939		940		941	
942		943		944		945	
946		947		948		949	
950		951		952		953	
954		955		956		957	
958		959		960		961	
962		963		964		965	
966		967		968		969	
970		971		972		973	
974		975		976		977	
978		979		980		981	
982		983		984		985	
986		987		988		989	
990		991		992		993	
994		995		996		997	
998		999		1000		1001	
1002		1003		1004		1005	
1006		1007		1008		1009	
1010		1011		1012		1013	
1014		1015		1016		1017	
1018		1019		1020		1021	
1022		1023		1024		1025	
1026							

Important Safety Information

INDICATION AND USAGE

CYTALUX® is an FDA approved optical imaging agent indicated as an adjunct for intraoperative identification of:

- Malignant lesions in adult patients with ovarian cancer.
- Malignant and non-malignant pulmonary lesions in adult patients with known or suspected cancer in the lung.

WARNINGS AND PRECAUTIONS

Infusion-Related Reactions

Adverse reactions including nausea, vomiting, abdominal pain, flushing, hypersensitivity, elevation in blood pressure, dyspepsia, and chest discomfort were reported in patients receiving CYTALUX in clinical studies. A total of 17% of patients experienced reactions during administration of CYTALUX. Reactions typically occurred within 15 minutes of the start of infusion. CYTALUX infusion interruption or discontinuation due to adverse reactions occurred in 11% of all patients. Treatment with antihistamines and/or anti-nausea medication may be used. If an adverse reaction occurs during administration, the infusion can be interrupted and resumed after treatment of the reaction.

Risk of Misinterpretation

Errors may occur with the use of CYTALUX during intraoperative fluorescence imaging to detect ovarian cancer and lesions in the lung, including false negatives and false positives. Non-fluorescing tissue in the surgical field does not rule out the presence of ovarian cancer or lesions in the lung. Fluorescence may be seen in normal tissues including bowel, kidneys, lymph nodes, lungs, and inflamed tissue.

Embryo-Fetal Toxicity

Based on its mechanism of action, CYTALUX may cause fetal harm when administered to a pregnant woman.

Advise females of reproductive potential of the potential risk to a fetus. Verify pregnancy status of females of reproductive potential prior to initiating CYTALUX treatment.

Risk of Pafolacianine Aggregation and Infusion Reactions

Use of the incorrect diluent to prepare the CYTALUX infusion solution can cause the aggregation of pafolacianine; aggregation may induce infusion reactions such as nausea, vomiting, abdominal pain or rash. Use only 5% Dextrose Injection to prepare the CYTALUX infusion solution. Do not use other diluents.

DRUG INTERACTIONS

Use of folate, folic acid, or folate-containing supplements may reduce binding of pafolacianine to folate receptors and could reduce the detection of lesions with CYTALUX. Avoid administration of folate, folic acid, or folate-containing supplements within 48 hours before administration of CYTALUX.

ADVERSE REACTIONS

The safety of CYTALUX was evaluated in four open label clinical studies, two studies (N = 44 and N = 150) in patients with ovarian cancer and two studies (N = 100 and N = 112) in patients with known or suspected cancer in the lung. A total of 406 patients received 0.025 mg/kg of CYTALUX via intravenous administration. Adverse reactions that occurred in $\geq 1\%$ of patients were: nausea (13%), vomiting (5%), abdominal pain (2%), flushing (2%), other infusion-related reactions (2%), hypersensitivity (2%), elevation in blood pressure (1%), dyspepsia (1%), and chest discomfort (1%). Adverse reactions occurred during the administration of CYTALUX in 17% of patients.

See full Prescribing Information to learn more.

